About Us

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies.

About Genmab

Company overview

More information about our company

Core Values

Core purpose and values

We have a strong company culture: What drives our employees?


Senior leadership

Experienced international management group



Read more about our past